Literature DB >> 20425406

Chemoimmunotherapy with modified dosing of fludarabine, cyclophosphamide, and rituximab shows significant clinical activity in patients with previously untreated chronic lymphocytic leukemia.

Nicole Lamanna1, Mark A Weiss.   

Abstract

Entities:  

Year:  2009        PMID： 20425406     DOI： 10.1007/s11899-009-0034-1

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN： 1558-8211            Impact factor:   3.952


× No keyword cloud information.
  6 in total

1.  Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia.

Authors:  Neil E Kay; Susan M Geyer; Timothy G Call; Tait D Shanafelt; Clive S Zent; Diane F Jelinek; Renee Tschumper; Nancy D Bone; Gordon W Dewald; Thomas S Lin; Nyla A Heerema; Lisa Smith; Michael R Grever; John C Byrd
Journal:  Blood       Date:  2006-09-28       Impact factor: 22.113

2.  Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy.

Authors:  M A Weiss; M Glenn; P Maslak; Z Rahman; A Noy; A Zelenetz; D A Scheinberg; D W Golde
Journal:  Leukemia       Date:  2000-09       Impact factor: 11.528

3.  Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.

Authors:  Barbara F Eichhorst; Raymonde Busch; Georg Hopfinger; Rita Pasold; Manfred Hensel; Cordelia Steinbrecher; Siegfried Siehl; Ulrich Jäger; Manuela Bergmann; Stephan Stilgenbauer; Carmen Schweighofer; Clemens M Wendtner; Hartmut Döhner; Günter Brittinger; Bertold Emmerich; Michael Hallek
Journal:  Blood       Date:  2005-10-11       Impact factor: 22.113

4.  Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.

Authors:  Michael J Keating; Susan O'Brien; Maher Albitar; Susan Lerner; William Plunkett; Francis Giles; Michael Andreeff; Jorge Cortes; Stefan Faderl; Deborah Thomas; Charles Koller; William Wierda; Michelle A Detry; Alice Lynn; Hagop Kantarjian
Journal:  J Clin Oncol       Date:  2005-03-14       Impact factor: 44.544

5.  Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

Authors:  John C Byrd; Kanti Rai; Bercedis L Peterson; Frederick R Appelbaum; Vicki A Morrison; Jonathan E Kolitz; Lois Shepherd; John D Hines; Charles A Schiffer; Richard A Larson
Journal:  Blood       Date:  2004-05-11       Impact factor: 22.113

6.  Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses.

Authors:  Nicole Lamanna; Joseph G Jurcic; Ariela Noy; Peter Maslak; Alison N Gencarelli; Katherine S Panageas; Mark L Heaney; Renier J Brentjens; David W Golde; David A Scheinberg; Andrew D Zelenetz; Mark A Weiss
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 50.717
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.